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INTRODUCTION 
 
The principle bile pigment is bilirubin. The end product of heme catabolism is 
bilirubin.Previously there was a belief that the bilirubin was a toxic 
waste.However, contrary to earlier there which is highly a potent one recent 
research proved that bilirubin is physiological antioxidant.Atherosclerosis and 
inflammation as well coronary artery disease are protected by bilirubin. 
 
Lipid oxidation and oxygen radicals are primarily responsible for the development 
of Coronary Artery Disease. Arterial plaque formation and atherosclerosis have 
two leading elements viz., lipid oxidation and oxygen radical formation. 
Theformation of oxygen and peroxyl radicals leads to atherosclerosis and 
inflammation. 
 
It is widely known that bilirubin has antioxidant properties. It has role to protect 
the atherosclerotic process by preventing oxidized LDL formation. Bilirubinis 
capable of providing potent scavenging effect of peroxyl radicals. Such capability 
arises out of increase in the circulatory bilirubin.  
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The circulatory bilirubin plays a physiologic role to protect against the diseases 
where oxygen and peroxyl radicals are involved.Smoking, blood cholesterol and 
hypertension are leading risks that contribute for the ischemic heart disease. 
 
The Antioxidants havedietary as well as endogenous protective 
characteristics.Therefore, more the serumbilirubin concentration higher the 
prevention of LDL oxidation, eventually the risk of ischemic heart disease is 
reduced1-3. The primary objective of this study dissertation is to test the hypothesis 
low serum bilirubin is a risk factor for ischemic heart disease. Besides, the 
dissertation identifies the association of serum bilirubin with multiple variables 
like age, sex, family history of coronary artery disease, smoking, hypertension, 
diabetes mellitus and lipid profile. 
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REVIEW OF LITERATURE 
FORMATION OF BILIRUBIN: 
The breakdown of heme present in hemoglobin,myoglobin, cytochromes, catalase, 
peroxidase and tryptophan pyrrolase led to the formation of bilirubin. Hemoglobin 
yields 80% of the daily bilirubin production (250 to 400 mg in adults). The 
remaining 20% of serum bilirubin are from hemoproteins and small poolof 
freehemewhich rapidly turnover. Conditionsassociated with increased red cell 
turnover such as intravascular or intramedullary hemolysis (eg, megaloblastic, 
hemolyticand dyserythropoietic anemia’s) results in enhanced bilirubin formation. 
Afour pyrrole ring connected by carbon bridges anda central ironatom 
(ferroprotoporphyrin IX) constitutes heme. The catalytic degradation of 
hemegenerates bilirubin. This sequential reaction is mediated by two groups of 
enzymes: viz., 
1) Hemeoxygenase 
2) Biliverdinreductase 
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Every haem molecule will produce one molecule of bilirubin. These molecules are 
found in haemoglobin and myoglobin. Also, cytochrome enzymes will also 
produce one molecule of bilirubin. 
 
The production of bilirubin from haem occurs mainly in the spleen (macrophages) 
and liver (Kupfer cells), but also all over the body by macrophages, and in renal 
tubular cells. Bilirubin-forming molecules (i.e. haem) are taken up by 
reticuloendothelial cells.  Inside these cells, Haemoxygenase enzymes break down 
the haem, removing iron (which is recycled) and carbon monoxide, leaving 
biliverdin. 
 
Biliverdin is very water soluble, whilst bilirubin is not.Biliverdin is then converted 
to bilirubin, whilst still in the reticuloendothelial cell. This is done by the enzyme 
biliverdinreductase.Bilirubin is not just a waste product. It takes up free radicals, 
and thus is an antioxidant. This is perhaps the benefit of not directly secreting 
biliverdin, but converting it to bilirubin first. 
 
After bilirubin is released from reticuloendothelial cells, it travels in the blood, 
bound to albumin. This ensures no bilirubin is excreted in the urine. At very high 
concentrations, bilirubin can slowly diffuse into the peripheral tissues where it is 
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toxic.Bilirubin is then removed from circulation in the sinusoids by hepatocytes. 
This is a passive process, which occurs down a concentration gradient. The fact 
that hepatocytes are in direct contact with the sinusoidal fluid helps this process.As 
soon as bilirubin enters the hepatocyte, it will become bound to 
glucuronyltransferase which conjugates the bilirubin ready for excretion. Bilirubin 
is joined with glucuronic acid in the conjugation process. Very small amounts of 
bilirubin will somehow evade this process and end up in bile as unconjugated 
bilirubin. 
 
Conjugated bilirubin (bilirubin di- and mono-glucuronide)  has the property of 
water solublity,.so  does conjucated bilirubin  easily  diffuses through the 
cytoplasm  afterwards secreted into the bile canaliculi by an  active process. From 
here conjugated bilirubin is excreted with the bile into the intestine. Bacterial 
enzymes which arepresent in the colon & terminal ileum hydrolyse the large 
molecule. The free bilirubin is then reduced to urobilinogen.  
 
Some part of the bilirubin is broken down to substances which is 
colourless.Hepatocytes produce urobilinogen& by the action of colonic bacteria 
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results in stercobilinogen. These substancesare oxidised later to yellow coloured 
urinary urobilin and brown coloured stercobilin excreted via fecaes. 
Most of the urobilinogen is excreted in the faeces; the remainder is absorbed in the 
terminal ileum, returned to the liver via enterohepatic blood, and again excreted 
into theintestine asbile. A small amount of the urobilinogen is excreted in the 
normal urine.In situations where the liver cannot excrete conjugated bilirubin, the 
kidneys will take over this job, however once plasma concentrations are high 
enough (above 600µmol/L) – the kidneys cannot conjugate bilirubin – only excrete 
if after this process has occurred. Bilirubin that is deconjugated by bacteria in the 
gut will be reabsorbed in the colon. 
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Antioxidant role of Bilirubin: 
Multiple studies have shown that different circulating forms of bilirubin are 
powerful antioxidants, viz. free bilirubin, albumin-bound bilirubin, unconjugated 
bilirubin and conjugated bilirubin.These forms of bilirubin are effective scavengers 
of peroxyl radicals .Besides they are able to protect human LDL (low density 
lipoprotein) against peroxidation4-8. 
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The increased physiological concentrations of plasma bilirubin reduces the risk of 
atherogenesis.The reasons being 
 
a) Involvement of oxidized LDL in the formation of atherogenic plaques 
 b)Under physiological conditions the abilityof bilirubin to serve as a potent lipid 
chain-breaking antioxidant9-10. 
 
 It is a established fact that bilirubin is a physiological antioxidant.This fact has 
been established over the years of experiments in humans and animals. 
 
Yamaguchi and others found that the oxidative metabolites of bilirubin 
(biotripyrrins) from the urine of healthy human’s11.And also they isolated the 
metabolites of bilirubin from ascorbic acid-deprived rats treated with endotoxin12. 
Feeding of ascorbic acid resulted in the reduction of bilirubin metabolites which is 
a physiological antioxidant.It also reduced the hepatic concentration of HO 
(hemeoxygenase) mRNA principally stimulated by endotoxins. 
 
Multiple studies  shows that lower bilirubin concentration results in higher 
incidence of coronary artery disease,vice versa higher bilirubin subjects had lower 
occurrence of coronary artery disease13.  
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It has also been established that below normal serum bilirubin level is associated 
with the presence of ischemic heart disease.Schwertner HA and Hopkins PN found 
that  patients with early familial CAD have an average total serum bilirubin of 8.9 
± 6.1 μmol/L and the average level in healthy control subjects is 12.4 ± 8.1 
μmol/Lwhich is significantly higher than coronary artery disease patients14. 
 
Briemer and others observed that cardiovascular risk and bilirubin level have U-
shaped relationship.Because of the existence of such relationship they firmly 
concluded that low concentrations of serum bilirubin are associated with increased 
risk of ischemic heart disease15. 
 
Schwertner and MadhavanM  on prolonged investigations found that multiple risk 
factors of CAD is inversely correlate with plasma bilirubin concentration. These 
risk factors are vizsmoking, LDL-cholesterol, obesity anddiabetes. They further 
found that the protective factors like HDL-cholesterol, lower FEV1, and lower 
serum albumin are directly correlating with serum bilirubin16,17. 
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On the basis of abovefindings, low bilirubin was found to be an independent risk 
factor for CAD. Between CAD morbidity and bilirubin concentration an inverse 
correlation was demonstrated.Hunt18,19and others work is an another testimony of 
the existence of this inverse relationship .They propounded a genetic variation in 
bilirubin concentration in individuals with early CAD displaying lower bilirubin 
than unaffected persons. 
 
Circulating bilirubin possesses cardioprotective capacity which in turn associated 
with reduced risk for CAD. It would be interesting to determine which form of 
circulating bilirubin is involved in this cardioprotective activity. 
 
Antioxidant activity attributable to any form of bilirubin same is the case with 
cardioprotective potential of bilibrubin.The known forms are free unconjugated 
bilirubin, protein-bound unconjugated bilirubin, delta bilirubin, or mono-
diconjugated bilirubin.The unconjugated and albumin-bound bilirubin are the 
predominant circulatory form of bilirubin in physiological conditions. 
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The ascertained conditions which alters the bilirubin level in the blood are 
 A) Protein binding 
 B) Acidosis 
 C) Hypoxia  
 D) Extent of hemolysis. 
 
However, it is uncertain whether these conditions actually modify the 
cardioprotective potential of bilirubin. Such of the two conditions are briefly 
explained in the succeeding paragraphs. 
 
1) Factors which modulate Protein bindingare 
a) Albumin concentration in plasma 
b) Drug concentrations which compete on binding 
c)  Acidosis. 
These factors are expected to affect the balance between bound unconjugated 
bilirubin instrumental and free (diffusible) form, instrumental in changing the 
penetration of unconjugated bilirubin into cells.  
 
2) Likewise,membrane integrity is altered by hypoxia. This alteration 
inmembrane integrity actually modulates transfering capacity of bilirubin. 
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These complex interactions necessitateto establish the antioxidative capacity of 
different bilirubin forms. Therefore it is imperative to assess how thebilirubin 
antioxidative capacity is altered by circulating concentration of blood pH,  free 
bilirubin,circulating albumin and the presence of drugs . 
 
Mechanism responsible for antioxidant activity of Bilirubin:  
The chain-carrying peroxyl radical is scavenged by billurubin. This process of 
scavenging is done by donating a hydrogen atom attached to the C-10 bridge of the 
tetrapyrrole molecule yielding a carbon-centered radicalBil• 
 
LOO• + Bil→ LOOH + Bil 
 
Bil• + LOO•→ Bil-OOL 
 
Bil• + O2←→Bil-OO• 
 
LOO• + BV →LOO-BV• 
 
Conjugated bilirubin and unconjugated bilirubin act as antioxidants. This 
antioxidant property protects human LDL from lipid peroxidation. It is further 
interesting to note that scavenging activity of bilirubin against peroxyl radicals 
(generated by 2,2'-azobis [2-amidinopropane] dihydrochloride) is established  in 
vitro studies also. H2O2concentration to the magnitude of 10,000 and above 
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isprotected by bilirubin. This action can be done at the concentration as low as 10 
nM. Earlier it was believed that α-tocopherol was most effective in preventing lipid 
peroxidation20.However,it was established later that bilirubin provides better 
protection than α-tocopherol in preventing lipid peroxidation under physiologic 
conditions. Naturally a pertinent question arises as the bilirubin is the abundant 
endogenous antioxidant. It was established by recent researchers bilirubin is the 
predominant endogenous antioxidant in mammalian tissues.  
The prominent endogenouscytoprotective antioxidantsare glutathione and bilirubin. 
Bilirubin is an excellent antioxidant in tissues,eventhough the level of bilirubin is 
thousands times lower than glutathione.This is because of the action of 
biliverdinreductase which converts biliverdin into bilirubin as soon as biliverdin 
forms.It has shown that glutathione possess water soluble property protects water 
soluble proteins from oxidation.On the contrary because of its lipophilic nature 
bilirubin protects lipids against oxidation. Multiple studies proved that depletion of 
glutathione &biliverdinreductase augments cell death. A study conducted in mice 
after deleting heme oxygenase-2, which actually generatesbiliverdin,.Ultimatetly 
they found glutathione depleted mice showed predominant oxidation of protein, 
whereas biliverdinreductase deficient showed higher amount of lipid oxidation. 
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The role of Bilirubin in neonates:        
 
Neonates are not exception to this theory. In newborn infants a linear relationship 
has been identified between unconjugated bilirubin concentration and its plasma 
antioxidant capacity. This finding confirmsthat bilirubin is a significant plasma 
antioxidant.There is also a moderate increase in plasma bilirubin which may be 
favourableto infants under oxidative stress. 
 
Briemer LH and others found, the breakdown of heme which is a 
prooxidantmoleculethat yields biliverdin (immediately converted into bilirubin), 
iron, and carbon monoxide.  
 
The highly active constitutive isoform isHeme Oxygenase-2 in neurons. This 
accounts for most of the HemeOxygenase activity in the brain. Bilirubin 
production can be limited by destroying HO-2 gene. This decreased bilirubin 
production eventually leads to increased oxidative damage following cerebral 
ischemia21. 
 
We have already seen that serum bilirubin possess a U-shaped relationship not 
only with the incidence of ischemic heart disease but also with the outcome of 
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ischemic heart disease. Significantly bilirubin perfusion is capable of decreasing 
infarct size caused by IHD. Naturally the upper range of normal values of serum 
bilirubin concentration protects against the coronary artery disease. Conversely, 
concentrations in the lower range increase the atherogenicrisk and eventual risk of 
ischemic heart disease22. 
Prevention of Atherosclerosis: 
Several mechanisms have been found to be active in the antiatherogenis besides 
cardio protective effects of bilirubin.The concerned mechanisms are described 
below: 
a)Lipid oxidation inhibition by bilirubin : 
Among the Lipoproteins, notably LDL, are extremely prone to oxidation.The 
uptake of oxidized LDL by intimal macrophages is the key step in 
atherogenesis.This process eventually results in the accumulation of lipid-rich 
foam cells. It is possible that bilirubin protects lipids and lipoproteins against 
oxidation as bilirubin possess anti-oxidant capacity.  
The advantage of this process protects the vascularity 
againstatherogenesis.Therefore low bilirubin concentration is associated with 
increase in the oxidizedlipoproteins and lipids.This increased oxidation of lipids 
results in enhancedformation of atherogenic plaque in blood vessels13,23. 
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The picture shows the role of HO/CO in stenosis and neointima formation:  
(A)decreasein concentration of HO-1 causes vascular smooth muscle cell 
proliferationthis in turn eventually leads to stenosis.  
(B)On the contrary the increased  levelof HO-1,prevents neointimal formation by  
inhibiting vascular smooth muscle cell proliferation. 
(C)Healthy tissue is  produced by this protective healthy tissue. 
 
b) Enhanced( HO )HemeOxygenase activity of bilirubin: 
Increased Hemeoxygenase activity of bilirubin results in antiatherogenic and 
cardioprotective effects. Hemeoxygenase activity of  bilirubinis due to the changes 
in following metabolites:via 
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Moreover , hemoglobin being a scavenger of Nitric oxide is capable of blunting 
nitric oxide dependent vasodilatation. 
 
Role of carbon monoxide: 
Carbon  monoxide has the characteristic of affecting  cardiovascular function 
through activation of soluble guanylatecyclase.It consequently  increases 
intracellular cGMP concentration. By inhibiting platelet aggregation  and vascular 
smooth  
muscle cell proliferation, carbon monoxide acting as a vasodilator which regulates 
vasomotor tone25. 
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 Role of hemoxygenase:   
 A correlation exists betweenHemeoxygenase -1 activity and coronary artery 
disease risk.This is substantiated by property of Hemoxygenase -1 which changes 
the concentration of iron stores by releasing iron26.This theory has been validated 
by the study in mice which lacks   HO-1 develops anemia.The mice subjected to 
this study were found to have low serum iron level .And alsoiron was collected in 
the liver and kidney. These iron stores were found to injure the tissues in the 
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   The above  picture shows that increased expression  of HO-1not only  decreases  
the cytostatic effects of Angiotensin II but also attenuate  degradation of DNA 
which is measured by COMET assay. p21 and p27 are inhibited by CO which in 
turn increases cell-cycle progression.Bilirubin inhibitsROS-dependent degradation 
of DNA. 
 
Balla G and co- workers found that increased expression of ferritinwas due to the 
induction of Hemeoxygenase by heme28. Based on this finding it was further found 
the synthesis of ferritin was driven by iron released through hemooxygenase 
activity.The resultant ferritin possesses iron binding capacity.Therefore, 
endothelial cells are protected from oxidative damages.  
 
 
 
 30 
 
 
 
a)Immune reactions and inflammatory processes: 
 
Now let us see the association of bilirubin in immune reactions and inflammatory 
processes, which is a well demonstrated process.In vitro studies by Nakagami 
found that complement mediated reactions are inhibited by bilirubin and 
biliverdin29. While studying in the guniea pig he further observed that 
administration of biliverdin inhibits Forssmann anaphylaxis. On the basis of these 
findings one can easily discerned that bile pigments are endogenous tissue 
protectors.This was possible because of their anticomplement activity .  
 
      Attempts were made to study the existence of relationship between bilirubin 
metabolism and inflammatory processes.It was found that high HO activity and 
faster resolution of inflammation are linked together.On the contrary it was 
observed that the inflammatory responses are potentiated by inhibition of this 
hemeoxygenase enzyme30. 
 
Both endothelial and inflammatory cells havenecessary enzymes which are 
responsible for bilirubin synthesis and degradation31. Cellular bilirubin levels are 
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primarily regulated by these enzymes. This finding establishes a wide 
physiological role for this endogenous bile pigment in regulating inflammation. 
 
Leukocyte recruitment is mediated by VCAM-1(Vascular cell adhesion molecule-
1) which is one of the steps in the process of inflammation. This process of 
inflammation was observed in number of inflammatory conditions, like 
atherosclerosis32,32 and inflammatory bowel disease34,35. 
 
 With regard toatherosclerosis, VCAM-1 is detectable in atherosclerotic plaques.At 
sites predisposed to atherosclerosis it was found that endothelial expression of 
VCAM adhesion molecule is an initial event36. 
 
       A study was conducted in the atherosclerotic -prone low density lipoprotein 
receptor knockout mouse. Where in significant decrease in the number of vascular 
lesions is noticed due to disruption of VCAM-1 expression.By inhibiting VCAM-1 
signaling bilirubin modulates the process of atherogenesis.Several epidemiological 
analyses conducted by Hopkins, Madhavan establishesan inverse correlation 
between risk and severity of cardiovascular disease and serum bilirubin level37, 38, 
39,40. 
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Measuring antioxidant property of bilirubin: 
 
     The antioxidant property of bilirubin is measured with the help of ferric 
reducing ability of plasma. At low PH ferric complex is reduced to ferrous ion 
which is measured as blue colour with absorption maximum at 593nm.By this 
assay it was measured bilirubin has antioxidant activity of 4.0, which is double that 
of uric acid, ascorbic acid,tocopherol. So it was measured that bilirubin protects the 
gut &liver from oxidative damage. This actually augments the defensing system 
when other mechanism fails. 
 
Bilirubin and markers of oxidative stress: 
 
Advanced glycation end products(AGEs), such as N-carboxymethyl lysine (CML) 
or pentosidine, are formed through the interaction ofplasma proteins with 
sacharide41 Oxidation productsAGEs activate NF-kB with 
subsequentoverexpression of proinflammatory genes includingCRP related also to 
chronic inflammation and correlatewith inflammatory markers, such as CRP, 
ESR,leukocyte or platelet count42,43. 
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Bilirubinvs Inflammation: 
 
      Inflammation and oxidative stress are vital in the pathogenesis of 
atherosclerosis. Multiple studies shown there is a strong inverse correlation 
between serum bilirubin and highly sensitive C reactive protein (hsCRP).This 
observation supports the presumption thatatherogenesis is subdued by bilirubin. 
This action is mediated through inhibition of systemic inflammatory response by 
bilirubin44-49. 
 
The anti-inflammatory actions of bilirubin are mediated by the following 
mechanisms: 
¾ Has anticomplement effects 50 
¾ Attenuates liver injury in a rat model of endotoxemia51 
¾ Blocks oxidant-mediated activation of leukocytes 52 
¾ Attenuates vascular endothelial proliferation via inhibition of NFkB53 
¾ Inhibits transendothelial leukocyte migration via suppression of 
VCAMsignaling a process implicated in the pathogenesis54ofnumerous 
diseases, includingInflammatory Bowel 
Disease55,conjunctivitis56,nephropathy57, arthritis58,systemic collagenoses59 
and possibly cancer60. 
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Bilirubin and rheumatological diseases: 
There is an inverse relationship between bilirubin levels and various 
rheumatological disorders. 
 
¾ Systemic lupus erythematosus,61 
¾ Rheumatoid arthritis 62 
¾ Wegener granulomatosis63 
 
There is striking inverse association betweenserum bilirubin levels and 
SLE.Antioxidant defense systems efficiency is related to theprognosis of patients 
with SLE64.Further studies must reveal whether low serum bilirubin levelsare 
caused by theconsumption of bilirubin during severe SLE-mediated oxidativestress  
orby the genetic predisposition of affected subjects.65.The same principle might 
also apply forRheumatoid arthritis andWegenergranulomatosis, where similar 
results have been detected. 
 
Bilirubin in neurologic andpsychiatric diseases:  
Inverse association between serum bilirubin levels andamyotrophic lateral sclerosis 
66, depressions67.The nocturnal bilirubin levels are found to be lower in depression 
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patient when compared to controls. Serum bilirubin is an important predictor of 
oxidative stress-mediated diseases including autoimmune, neurologic and 
psychiatric conditions. 
 
Recent human studies establish that bilirubin has important physiological property 
because of the fact that higher bilirubin levels correlate with better 
cardiovascularoutcomes. 
 
In Gilbert’s syndrome (UGT1A1): 
Mild hyperbilirubinemia occurs in people with Gilbert’s syndrome.The prevalence 
of ischemic heart diseasehas a dubious distinction of having a relatively low 
percentage (2%)as against thegeneral population (12%)68. 
 
The gene UGT1A1 codes for a liver specific glucoronosyltransferase that converts 
bilirubin into a more lipid soluble form the body is able to excrete.Homozygosity 
at the polymorphic promoter repeat locus UGT1A1 *28 leads to decreased ability 
of the enzyme to metabolize bilirubin and subsequent mild hyperbilirubinemia69. 
 
In patients with Gilbert’s syndrome, smaller brachial artery diameter in 
hyperbilirubinemic patients is consistent with significant decrease in 
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cardiovascular disease. Brachial artery diameter and to a lesser degree cold pressor 
test were significantly associated with genotype at the UGT1A1*28 locus, 
providing compelling evidence that bilirubin affects CVD through pathways 
associated with artery size such as vasomotor tone,reactivity and  possibly arterial 
wall structure70. 
 
  The Framingham offspringstudy found that higher serum bilirubin levels were 
associated with lower risk of cardiovascular disease in men.It was also found by 
same study the subjects who are homozygous for the UGT1A1*28 allele,have 
higher serum bilirubin levels, eventually decreases the risk of cardiovascular 
disease71. 
 
Another study was   conducted by LauraJ.Horsfall, Irwin Nazareth, and Irene 
Petersen in United Kingdom to explore the association between bilirubin and CAD 
in statin drug using population. In this study they found persons with lower range 
ofbilirubin(0.06-0.35mg/dl) had higher incidence of CAD compared to higher 
range of bilirubin(1.1-2.3mg/dl). In comparison patients with 0.3mg/dl bilirubin  
had 18% higher risk of CAD with a similar CVD risk profile higher bilirubin 
population(0.6mg/dl).And also they had 34%higher  mortality.They conclude that 
serum bilirubin is an independent risk factor for developing CAD and mortality. 
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Bilirubin in females: 
    In females the bilirubin level is not that much reliable because it is affected by 
estrogen which increases it’s metabolism. 
 
Role of bilirubin in peripheral vascular disease: 
TheNational Health and Nutrition Examination Survey observed that increased 
serum total bilirubin level correlates with decrease in the incidence of peripheral 
arterial disease.Ultimately low serumbilirubin levels correlated with increased 
carotid intima-mediathickness and impaired flow-mediated dilation which predicts 
cardiovascular disease in normal healthy individuals. Finally these findings led to 
the conclusion that increased bilirubin levels decrease the risk of cardiovascular 
disease in normal subjects72. In this study they arrives that 0.1mg/dl increase in 
bilirubin associated with 6% reduction in peripheral vascular disease. 
 
Smoking vs. serum bilirubin: 
Cigarette smoking increases oxidative stress.This oxidative stress increases level of 
markers of lipid peroxidation in plasma. Smoking induces oxidation of lipids due 
to exposure to LDL. It also increases the uptake of modified LDL by macrophages. 
It has already been established that smoking  lowers serum bilirubin concentration 
in males. 
 38 
 
Bilirubin is considered tobe a potent antioxidant by inhibiting both lipid and 
proteinoxidation, under physiological conditions. Oxidative stress and 
inflammationare fundamental to the arteriopathy. Additionally, bilirubin exerts 
anti-inflammatory effects on vasculature. Bilirubin is also capable of acting against 
plaqueformation and eventual atherosclerosis. The association between bilirubin 
andperipheral artery disease and carotid intima-mediathickness (IMT) is well 
established doctrine as of today73-75. 
 
 The role ofbilirubin in coronary artery calcification: 
People with higher bilirubin concentration are less likely to develop coronary 
artery calcification (CAC) score. This observation is based on the potential 
antioxidant and anti-inflammatory properties of bilirubin .Other contributing 
factors for this action such as oxidative stress, anti-inflammatory role and cellular 
injuries in atherosclerosis.Recentstudy establishesthat coronary artery calcification 
score as a newer  marker of coronary atherosclerosis. It is a quantitativeobjective 
measure of coronary artery atherosclerosis.This CAC score is assessed by a 
noninvasive testmultidetectorcomputed tomography (MDCT). In addition, CAC 
scoresare related with risk factors for coronaryartery disease and cardiovascular 
events76. 
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Independent inverse associationbetween serum total bilirubin and CAC score in 
males was inferred from this study.This again emphasis lowserum bilirubin 
concentration is aoverwhelming risk factor for CAC in males. Moreover, the 
bilirubin reduces the CAC score by lowering the hsCRP level77. 
     Serum bilirubin levels were found to be higher in vegetarians than non –
vegetarians. Possibly lower calorie intake may have resulted in higher bilirubin 
levels because fasting increases bilirubin. 
Higher altitudes have been associated with increased bilirubin because of increased 
hematopoietic response. 
In future the extensive research in this field wouldmainly be focuson the 
following components: viz 
¾ The complex interactions between HO expression,  
¾ The circulating concentrations of its substrate and products,  
¾ The effect of these components, and specifically of bilirubin,  
¾  Bilirubin action on the vasculature, 
¾ Bilirubin role on lipid metabolism 
¾ Bilirubin effect  on the cardiovascular system  
Which will be cleared in the fore coming years. 
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AIM 
The aim of this study is,to investigate the relationship of serum bilirubin with 
coronary artery disease patients in comparison with non-coronary controls. 
To identify whether any association exists between serum Bilirubin level and the 
following parameters. 
¾ Age 
¾ Sex  
¾ Blood pressure 
¾ Dyslipidemia 
¾ Diabetes mellitus 
¾ Smoking 
¾ Body mass index  
¾ Family history of CAD 
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BACKGROUND 
SELECTION OF SUBJECTS: 
Patients who attended cardiac outpatient department in Kilpauk Medical College 
Hospital with past history of Myocardial infarction were enrolled in cases after 
excluding exclusion criteria. 
Control subjects are taken from general medicine outpatient department after 
verifying inclusion and exclusion criteria via questionnaire. 
INCLUSION CRITERIA: 
Cases:Cardiovascular disease was diagnosed who fulfill the following criteria: 
Subjects who had  
1)Myocardial infarctionevidenced by electrocardiogram (ECG)abnormalities and 
enzyme changes. 
 2) Coronary bypass surgery or percutaneous coronary interventions. 
 3) Significant stenosis on coronary angiogram. 
4) An unequivocally positive stress ECG.  
 
Evidence of coronary artery disease within 5 yrs of duration which is confirmed by 
ECG,ECHO and previous cardiac records are taken as cases. 
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Controls : Those without CAD matched with age and other co-morbid conditions 
are taken as control subjects. 
EXCLUSION CRITERIA 
¾ Known liver disease 
¾ Acoholism 
¾ Fever with jaundice 
¾ Cerebro vascular accident 
¾ Chronic kidney disease 
¾ Haemoglobin <10g >20g 
¾ Malignancy 
¾ CAD with failure 
¾ Hepatotoxic  drug intake 
¾ Hemodynamic instability 
¾ Autoimmune disease 
¾ Chronic obstructive pulmonary disease 
¾ Chronic or current infections 
¾ Use of anti-inflammatory drugs in the past 30days 
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MATERIALS AND METHODS 
Setting:Kilpauk Medical College 
Study design: Descriptive analytical study 
Period of study: 2010 May -2012 December 
Sample size: 200subjects (100 cases + 100 controls) 
This study is to compare the serum bilirubin level between CAD and non CAD 
subjects and its significance among them.And also to identify whether any 
association exists between age, sex, blood pressure, dyslipidemia,diabetes,smoking 
and CAD with serum bilirubin level. 
Both cases and controls are investigated by following measures. 
1) History –duration of CAD, symptoms,family history of 
CAD,smoking,alcohol intake,past history of jaundice were asked. 
2) General examination 
3) Systemic examination 
4) Blood pressure by sphygmomanometer 
5) Body mass index calculation 
6) Complete blood count 
7) Renal function test 
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8) Complete Liver function test including serum Total bilirubin,Direct 
bilirubin,Indirect bilirubin,liver enzymes (AST,ALT,SAP),Total protein 
,Albumin,Globulin. 
9) Viral markers HBsAg, HCV IgM 
10) Fasting lipid profile (Total cholesterol,LDL,HDL) 
11) 12lead ECG 
12) ECHO –in transthoracic ECHO LV dysfunction,LV hypertrophy,ejection 
fraction ,valve sclerosis,calcification are noted. 
 
Biochemical analysis  
After an overnight fast, blood samples were taken in the morning. Total plasma 
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and triglycerides 
(TG) were analyzed in laboratory. With the help of Friedewald formulaLDL-
Cholesterol was calculated.  
Total serum bilirubin was measured in the laboratory by spectrophotometry 
method. In the Jendrassik-Grof allied methods, total bilirubin (including direct 
bilirubin) is reacted with diazotized sulfanilicacidin an acidic medium to form 
azobilirubin. In theabsence and in the presence of “accelerator” substances 
mostcommonly caffeine and sodium benzoate, althoughseveral others have been 
proposed -direct and totalBilirubin, respectively, are quantified.  
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The absorbance of theazopigment thus developed is then measured as such 
fordirect bilirubin, or, for total bilirubin, after treatment withalkaline tartrate 
solution, which shifts the absorption maximumof the azopigment toward longer 
wavelengths. 
 
DATA ANALYSIS: 
Statistical analysis  
Mean values of all parameters in subgroups were calculatedby independent 
sample-t-test. To compare the distributions of dichotomous data viz .,gender, 
smokers, presence of hypertension or diabetes and bilirubin levels , Chi-square 
testwas used . Association between CVD and bilirubin levelwas assessed by 
logistic regression model. Potential confounders, i.e., hypertension, diabetes, age, 
gender ,body mass index (BMI), HDL-C and TG were adjusted . 
 
Pearson correlations were applied to evaluate the correlation between 
absolutechanges in bilirubin,AST,ALT,Age,sex,BMI,Hypertension,Diabetes 
mellitus,lipid profile.  
All statistical analyses were performed using the SPSS(software package used for 
statistical analysis) package .A p-value of less than 0.05 was considered to be 
statistically significant. 
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OBSERVATION ANALYSIS 
SEX  GROUP 
 Table 1 
Crosstab 
 GROUP Total 
Cases Control 
SEX 
F 
Count 28 43 71
% within SEX 39.4% 60.6% 100.0%
% within GROUP 28.0% 43.0% 35.5%
% of Total 14.0% 21.5% 35.5%
M 
Count 72 57 129
% within SEX 55.8% 44.2% 100.0%
% within GROUP 72.0% 57.0% 64.5%
% of Total 36.0% 28.5% 64.5%
Total 
Count 100 100 200
% within SEX 50.0% 50.0% 100.0%
% within GROUP 100.0% 100.0% 100.0%
% of Total 50.0% 50.0% 100.0%
 47 
 
 
 
 Fig 1 
In this study the total no of males contribute 64.5% .females 35.5%.In cases males 
are higher 36%,females 14%. But in controls females are 21.5%, males 
28.5%.There is significant difference in in age group in cases and controls. The P 
value is 0.027. Males are  significantlyhigher in cases, shows higher incidence of 
cardiovascular disease in males. 
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DM  GROUP 
 Table 2 
 
The diabetic patients in this study group is 26.5%.in cases 13.5%.incontrols 
13.0%.the difference in diabetes population between cases andcontrol are not 
significant. 
 
 
 
 GROUP Total 
1 2 
 
DM 
Count 27 26 53
% of Total 13.5% 13.0% 26.5%
Non-DM 
Count 73 74 147
% of Total 36.5% 37.0% 73.5%
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The above finding is shown in the following graph : 
 
 
 Fig 2 
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HYPERTENSION GROUP 
 
 
 Fig 3 
In this study hypertensive population is 30%.each contributes 15%.there is no 
significant difference between two groups. 
 
0
10
20
30
40
50
60
70
80
HT Non‐HT
Cases
Control
 51 
 
FAMILY HISTORY OF CAD 
 
 
 Fig 4 
The family history of CAD is present in 9.5% of cases, 9.5% of  
controls. There is no difference in regards to family history. 
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SMOKING GROUP 
 
 
 Fig 5 
In cases smokers are 11%. In controls smokers 11.5%.overall in this study smokers 
are 22.5%. non smokers are 77.5%.there is no significant difference between two 
groups. 
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TYPE OF MI  GROUP 
Type of MI No.of Cases Percentage 
AWMI 72 72% 
IWMI 28 28% 
 Table 3 
 
 
 Fig 6 
In cases anterior wall MI is more common than inferior wall MI 
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IWMI
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THE MEAN VALUES 
 Table 4 
 
 
 
 
 
 
 
 Table 5 
 
 
 
 
 
 
 
AGE  MEAN VALUE 
 GROU
P 
N Mean Std. 
Deviation 
Std. Error 
Mean 
AGE 
1 100 61.87 15.913 1.591
2 100 56.47 11.026 1.103
 Sig. (2-tailed) Mean Difference
AGE 
Equal variances 
assumed 
.006 5.400
Equal variances not 
assumed 
.006 5.400
 55 
 
 
 Fig 7 
The mean age level of Group 1 and Group 2 are statistically significant. 
The p value is 0.006.the mean age in cases is 61.87, in control 56.47.in 
cases people are elder than   control   group. 
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DURATION OF CAD 
 
 Table 6 
GROUP  N Mean Std. 
Deviation 
Std. Error 
Mean 
DURATION OF 
CAD 
 100 3.16 2.642 .264 
 . . . 
 
 
The mean duration of CAD in study group is 3.16 years. 
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LIPID   PROFILE 
 
 
Sig. (2-tailed) 
TC  
Equal variances assumed .002 
Equal variances not assumed .002 
LDL  
Equal variances assumed .000 
Equal variances not assumed .000 
HDL  
Equal variances assumed .000 
Equal variances not assumed .000 
 Table 9 
 
The difference of LDL,HDL,Total cholesterol between cases and control are 
statistically significant. In cases patients are having higher total cholesterol,LDL 
and low HDL.In  controls HDL level are higher,and low LDL,total cholesterol. 
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LIVER ENZYMES 
 Table 10 
 
 
 
 
 
 
 
 
The difference in AST and ALT are not significant between cases and controls. 
 
 
 
 
 
GROUP 
  
 Mean 
 
AST 
Cases 10.83 
control 11.00 
 
ALT 
cases 11.61 
control 10.94 
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The difference in serum total bilirubin between cases and control are  
statistically significant.The P value is 0.017 
DIRECT BILIRUBIN Table 13 
 
 
 
 
 
The mean value of direct bilirubin between cases and control are not significant. 
 
Table 12 
Sig. (2-tailed) Mean Difference 
TB 
Equal variances assumed .017 -.41930 
Equal variances not 
assumed 
.018 -.41930 
 GROUP N Mean Std. Deviation 
DB 
cases 100 .0787 .08183 
control 100 .0786 .08182 
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 Table 14 
 
 
 
 
 
INDIRECT BILIRUBIN 
 GROUP N Mean 
IB 
cases 100 .4047 
Control 100 .3900 
 Table 15 
The mean value of indirect bilirubin between cases and control are notstatistically  
significant. 
 
 
  P value  
DB 
Equal variances assumed .993 
Equal variances not assumed .993 
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BILIRUBIN IN RELATION WITH SEX: 
 
 
 
 
 
 
 
 
 
 
 
 Table16 
 
In association with sex and age there is no significant difference in  
serum bilirubin. 
 
 
 SEX N Mean 
TB 
M 72 .4824 
F 28 .4646 
DB 
M 72 .0833 
F 28 .0668 
IB 
M 72 .4053 
F 28 .4032 
 67 
 
ASSOCIATION OF SERUM BILIRUBIN WITH DIABETES MELLITUS 
 
Table 17 
 
There is no significant difference in serum bilirubin between diabetes and non 
diabetes population. 
 
 
 
 DM N Mean 
TB 
1 27 .4907 
2 73 .4725 
DB 
1 27 .0785 
2 73 .0788 
IB 
1 27 .3870 
2 73 .4112 
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 Fig 13 
 
 
The difference in serum bilirubin between diabetes and  non-diabetes populationis 
not statistically significant. 
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BILIRUBIN LEVEL IN HYPERTENSIVE POPULATION 
 Table 18 
 Table 19 
 
 HT N Mean 
TB 
1 30 .4203 
0 70 .5019 
DB 
1 30 .0537 
0 70 .0894 
IB 
1 30 .3660 
0 70 .4213 
 P value 
TB 
Equal variances assumed .013 
Equal variances not assumed .003 
DB 
Equal variances assumed .045 
Equal variances not assumed .004 
IB 
Equal variances assumed .057 
Equal variances not assumed .018 
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FAMILY HISTORY OF CAD WITH SERUM BILIRUBIN 
 Table 20 
 FH/CAD N Mean 
TB 
1 19 .4368 
0 81 .4869 
DB 
1 19 .0674 
0 81 .0814 
IB 
1 19 .3800 
0 81 .4105 
 
 
There is no significant association between family history of CAD and serum 
bilirubin. 
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SERUM BILIRUBIN LEVEL IN SMOKERS 
 Table 21 
 SMOKING N Mean 
TB 
1 22 .4541 
0 78 .4840 
DB 
1 22 .0709 
0 78 .0809 
IB 
1 22 .4086 
0 78 .4036 
  
 
The mean serum bilirubin in smokers are 0.45, the mean level in non smokers 0.48 
.the serum bilirubin levels are lesser in smokers than non smokers. But the 
difference is not statistically significant. 
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CORRELATION STUDY: 
By analysing with Pearson correlation there is an association between the 
following parameters. 
Mean values in cases and control 
                                         Table 22 
 
 
 
 
 
 
 
 
 
 
 Mean in cases Mean in controls 
AGE 61.87 56.47 
DURATION OF 
CAD 
3.16 
- 
BMI 23.17 23.23 
TC 163.95 153.49 
LDL 127.92 105.42 
HDL 42.96 52.06 
AST 10.83 11.00 
ALT 11.61 10.94 
TB 0.477 0.897 
DB .078 0.786 
IB .40 0.39 
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In  conclusion from correlation study is there is significant correlation at 
0.01level(pearson correlation) in the following parameters. 
 
BMI LDL,Direct bilirubin 
Total cholesterol LDL 
Total bilirubin LDL,Total cholesterol 
 
 
There is significant correlation at 0.05 level in the following parameters. 
Indirect bilirubin TC,LDL 
LDL Direct bilirubin 
ALT Direct bilirubin 
Indirect bilirubin Total bilirubin 
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Inference from correlation study: 
 The body mass index is directly proportional with LDL and Direct bilirubin. 
Higher the BMI higher the LDL cholesterol and higher the direct bilirubin.  
 
 Those who having higher total cholesterol also having higher LDL 
cholesterol. 
 
 The level of total bilirubin and indirect bilirubin is directly proportional with 
LDL cholesterol and total cholesterol. 
 
 LDL cholesterol is correlating with direct bilirubin. 
 
 ALT level is correlating with direct bilirubin level. 
 
 Indirect bilirubin is directly proportion with direct bilirubin. 
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DISCUSSION AND INTERPRETATION 
In this observational study I studied 200 patients .I analysed 100 patients  
who had coronary artery disease taken as cases, 100 patients who did not 
have coronary artery disease were taken as control group. 
 
All the patients underwent complete investigation and were analyzed whether any 
difference in serum bilirubin between cases and controls. Further  
assessment was done to find any association of serum bilirubin with  
multiple variables like age,sex,BMI,smoking,diabetesmellitus,hypertension, 
family history of CAD,duration of MI,type of MI,Lipid profile,Liver  
enzymes, LV function . 
• The mean age in case group is 61.8 years.The mean age in control group is 
56.47.the age is significantly higher in cases than control group. 
• The average duration of coronary artery disease is 3.16 years. 
• The mean body mass index in study group is 23 
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• Total cholesterol,LDL cholesterol are significantly higher in coronary artery 
disease patient. 
• HDL cholesterol is higher in control group acting as a protective factor. 
• The mean AST,ALT between two groups doesn’t have any significant 
difference. 
• Male population is higher in coronary artery disease group whereas females 
are higher in control group which shows higher risk in males 
• Diabetes mellitus population in study population is 23.5%.No significant 
difference between cases and controls. 
• 30% of people are hypertensive in study population.There is no significant 
difference between two groups. 
• Family history of CAD is present in 19% of study population.There is no 
difference between two groups. 
• Smoking history is present in 21.5%.there is no significant difference among 
cases and controls. 
• Anterior wall MI was present in 72%,Inferior wall MI was seen in 28%. 
• The mean total bilirubin in coronary artery disease patient is 0.47mg.the 
mean total bilirubin in non-coronary patient is 0.89mg.Case group has 
significantly lower bilirubin than control group. 
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• In association with age,sex,BMI, family history,smoking,type of MI,diabetes 
mellitus there is no significant difference in serum bilirubin between CAD 
and non- CAD patients. 
• The hypertensive population has significantly lower bilirubin than non- 
hypertensive population. 
• By analysing with pearson correlation,body mass index is directly 
proportional with LDL and Direct bilirubin. Higher the BMI higher the LDL 
cholesterol and higher the direct bilirubin.  
• Those who having higher total cholesterol also having higher LDL 
cholesterol. 
• The level of total bilirubin and indirect bilirubin is directly proportional with 
LDL cholesterol and total cholesterol. 
• LDL cholesterol is correlating with direct bilirubin. 
• ALT level is correlating with direct bilirubin level. 
• Indirect bilirubin is directly proportion with direct bilirubin. 
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Our results are consistent with findings(68,69,70) of both retrospective and 
prospective study. In these studies similar inverse correlation have been shown not 
only between serum bilirubin concentrations and coronary artery disease, but also 
between bilirubin and peripheral vascular disease, carotid intimamedia thickness 
and stroke-Meta analysis by novotynyetal, of eleven studies has shown an inverse 
and dose dependent relationship between serum bilirubin and different types and 
severities of coronary artery disease(71,72). 
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CONCLUSION 
I conclude this study with the observation is that coronary artery disease patients 
are found to have lower bilirubin level. This finding was established when the 
bilirubin levels in coronary artery disease patients werecompared with non-
coronary artery disease patients after matching the confounding factors.Therefore 
we may draw a irresistible conclusion that bilirubin plays a protective role against 
coronary artery disease. In other words, the assessment of serum bilirubin could 
very well be used to foresee the risk of coronary artery disease in case of high risk 
population. In order to prevent coronary artery disease ,drugs that increase the 
bilirubin in moderate level be used in future. 
 
Bilirubin is one of a series of endogenousantioxidants.These compounds operate in 
complex ways modulated by each other. This is possible due to exogenous 
antioxidant intake, as well as by the amount of oxidant stress experiences. Oxidant 
stress is believed to cause damage in atherosclerosis. The damage is caused by 
initiating lesions besides in aiding their progression to clinical events.Thus 
bilirubin may be working as a factor in the early phase of development 
ofatherosclerosis.This is so in the period closer to the onset of clinical events 
too.Plasma bilirubin concentration and coronary artery disease morbidityhave a 
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distinct inverse correlation and probably have an important clinical and diagnostic 
implication.  
 
The clinical relevance relates to potential preventive as well as therapeutic 
approaches. However, the diagnostic relevance emphasis  the plasma bilirubin 
concentration as a provisional new marker of atherogenic risk which can be 
measured in the clinical laboratory and applied in medical practice. 
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PROFORMA 
Name:                             Age:    sex:   
Place:       Occupation: 
History: 
Time since diagnosis of CAD: 
On treatment with: 
Diabetes mellitus: 
Hypertension: 
Past history of Jaundice: 
Family history of CAD:  
Smoking: 
Alcohol: 
Examination: 
Height:    Weight:     BMI: 
Pallor:    Icterus: 
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VITALS:  BP-   PR-    RR-    JVP- 
SYSTEMIC   EXAMINATION: 
CVS:        RS: 
ABDOMEN:  CNS: 
INVESTIGATIONS: 
Hb% RBS: 
Urea:                           Creatinine: 
Fasting serum Biliribin:  T-                       D-                 ID- 
Liver enzymes:AST                                     ALT              SAP 
Fasting lipid profile: 
ECG:Previous: Present:  
Chest X Ray: 
ECHO: 
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S.NO Name Age Sex
Duration of 
CAD (YRS) DM HT
Family 
History Smoker BMI BP Type of MI Lipid Profile Liver Enzymes
  Serum 
bilirubin EF
T.Chol LDL HDL AST ALT T D ID
1 Rajagopal 68 M 2.5 2 Yrs × × × 30.27 120/76 AWMI 186 126 38 18 12 0.8 0.5 0.3 60
2 Dhanavel 49 M 4 × × × ˇ 22.36 118/70 IWMI 136 154 42 10 10 0.51 0.11 0.40 55
3 Velu 51 M 1 × × ˇ × 20.5 120/80 AWMI 196 124 48 19 8 0.40 0.08 0.32 50
4 Srinivasan 59 M 1 × × × × 21.0 126/86 AW 176 126 52 10 18 0.52 0.12 0.4 48
5 Ravi 48 M 5 × × × ˇ 23.2 116/72 AW 126 146 38 12 14 0.36 0.08 0.28 50
6 Munusamy 60 M 4 × × × ˇ 25.3 136/80 IW 196 138 43 9 8 0.42 0.11 0.31 60
7 Dhanapal 65 M 5 ˇ × × × 18.6 116/68 IW 126 135 45 13 14 0.38 0.06 0.32 55
8 Heerolol 60 M 4 ˇ × × × 19.5 120/80 IW 135 145 36 10 12 0.46 0.09 0.37 60
9 Parvathy 55 F 3 × × ˇ × 32.8 130/90 AW 196 187 37 13 17 0.33 0.06 0.27 50
10 Muniammal 55 F 3 × × × × 20.5 110/70 IW 116 128 51 8 9 0.68 0.12 0.56 60
11 Meerbai 60 F 4 × × × × 19.8 130/80 IW 178 137 47 13 12 0.58 0.07 0.51 55
12 Murugesan 62 M 2 × × × × 18.7 110/70 AW 250 186 46 10 9 0.60 0.10 0.50 52
13 Perumal 52 M 4 × × × × 20.0 120/80 AW 153 154 63 21 36 0.49 0.09 0.40 55
14 Alagammal 64 F 3 × ˇ ˇ × 30.5 140/80 AW 225 145 38 17 13 0.36 0.06 0.30 54
15 Thomas 44 M 25 × ˇ ˇ × 19.5 146/90 AW 138 106 32 10 9 0.73 0.13 0.60 64
16 Nithyandan 53 M 2 × × × ˇ 19.5 110/70 AW 126 98 53 8 7 0.43 0.05 0.38 60
17 Ebeneser 48 M 1 ˇ ˇ × ˇ 22.0 130/80 IW 186 127 37 12 14 0.39 0.04 0.35 60
18 Egambaram 58 M 1 × ˇ × × 19.0 150/86 AW 225 176 39 8 7 0.54 0.09 0.43 60
19 Pattammal 70 F 5 ˇ ˇ × × 24.3 160/100 AW 169 142 43 9 9 0.31 0.03 0.28 55
20 Rajeswari 56 F 3 ˇ ˇ × × 20.5 130/90 IW 162 117 39 10 12 0.49 0.06 0.43 60
21 Aunasekaran 70 M 5 × × × × 31.6 126/76 AW 182 136 49 8 7 0.38 0.68 0.30 62
22 Gnanavel 58 M 4 × × × × 18.6 130/80 AW 182 146 46 10 12 0.66 0.06 0.60 45
23 Krishnamoorhy 78 M 3 × × × × 32.0 116/70 AW 210 186 37 8 9 0.42 0.05 0.37 55
24 Arunagiri 38 M 1 × × ˇ × 28.0 140/90 IW 132 115 42 12 12 0.56 0.08 0.48 60
25 Murugesan 48 M 2 × × × × 21.0 150/96 AW 187 153 36 7 6 0.32 0.02 0.30 45
26 Rajendran 53 M 5 × × × × 20.0 120/76 AW 226 176 42 8 9 0.39 0.05 0.34 56
27 Eswaran 84 M 5 × × × × 18.6 128/74 AW 176 132 46 9 12 0.47 0.06 0.41 52
28 Elumalai 76 M 3 × × × × 14.6 130/70 AW 118 92 59 10 7 0.63 0.08 0.55 60
29 Pangajam 84 F 4 × ˇ ˇ × 25.0 120/80 AW 159 136 38 9 9 0.36 0.04 0.32 48
30 Ramaya 69 M 5 × ˇ ˇ × 32.6 110/70 IW 192 146 39 8 6 0.28 0.04 0.24 45
31 Rose 63 M 3 × × × ˇ 19.7 120/80 IW 162 142 51 8 17 0.60 0.08 0.52 60
32 Anbumani 70 M 1 ˇ ˇ × ˇ 22.5 136/86 IW 136 96 48 9 12 0.48 0.06 0.42 55
33 Chinnasamy 45 M 0.5 × ˇ × × 21.0 110/70 AW 176 135 32 13 13 0.31 0.03 0.28 50
34 Kalyanakumari 58 F 4 ˇ ˇ × × 31.5 126/74 AW 116 86 45 6 8 0.52 0.07 0.45 60
35 Jone 63 M 4 ˇ ˇ × × 27.6 140/80 AW 189 147 36 12 13 0.39 0.04 0.35 55
36 Kubendran 57 M 3 × × × × 28.5 138/76 AW 142 110 49 10 10 0.44 0.04 0.40 60
37 Natarajan 48 M 2 × × × × 18.7 110/70 AW 179 139 39 7 8 0.43 0.04 0.39 58
38 Karthikeyan 64 M 2 × × ˇ × 21.1 130/76 AW 156 96 49 6 5 0.30 0.03 0.27 52
39 Chakravarthy 64 M 1 × × × × 22.5 156/86 AW 192 112 42 25 30 0.76 0.16 0.60 60
40 Sulthan Begum 58 F 1 × × × × 23.7 100/60 IW 165 127 37 12 13 0.47 0.07 0.40 55
41 Natesan 70 M 1 × × × × 24.8 110/70 AW 112 86 52 7 8 0.68 0.08 0.60 60
42 Sundaraj 63 M 5 × × × × 12.5 120/86 AW 132 114 36 12 12 0.54 0.07 0.43 55
43 Duraisamy 48 M 5 × ˇ ˇ × 38.5 140/90 AW 176 112 42 6 16 0.45 0.05 0.40 60
44 Leelarathi 55 F 2 × ˇ ˇ × 25.4 130/80 IW 167 121 48 10 10 0.52 0.06 0.46 55
45 Kumaravalli 58 F 4 × × × ˇ 26.5 120/70 IW 156 117 35 9 7 0.4 0.10 0.80 60
46 Sundaramoorthy 59 M 3 ˇ ˇ × ˇ 23.5 116/70 AW 213 176 41 10 10 0.37 0.04 0.33 52
47 Thulukanamma 65 F 5 × ˇ × × 20.0 130/74 AW 195 121 45 8 8 0.28 0.04 0.24 45
48 Kuppan 72 M 2 ˇ ˇ × × 25.6 118/70 AW 136 106 46 12 13 0.41 0.03 0.38 48
49 Ismail 64 M 1 ˇ ˇ × × 22.0 124/60 IW 166 136 38 10 10 0.39 0.1 0.29 40
50 Rani 51 F 1 × × × × 24.0 130/76 AW 146 106 45 8 9 0.51 0.07 0.44 50
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51 Manikam 52 M 3 × × ˇ × 30.5 120/80 IW 164 126 40 9 9 0.32 0.04 0.28 48
52 Vajravel 78 M 2 × × × × 21.5 120/70 AW 186 137 38 10 10 0.40 0.03 0.37 50
53 Srinivasan 38 M 1 × × × × 35.5 130/80 AW 146 168 42 8 8 0.36 0.02 0.38 55
54 Alagammal 45 F 2 × × × × 22.0 120/80 IW 156 127 38 15 17 0.39 0.03 0.36 45
55 Saraswathi 54 F 1 × × × × 20.5 120/80 AW 168 138 42 9 9 0.41 0.06 0.35 60
56 Ilavanan 48 M 2 × ˇ ˇ × 25.0 130/80 AW 126 98 46 6 6 0.54 0.06 0.48 55
57 Kannaiyan 66 M 1 × ˇ ˇ × 28.2 130/50 IW 172 121 36 10 10 0.37 0.05 0.32 60
58 Sundar 70 M 3 × × × ˇ 21.0 120/80 AW 156 113 42 8 12 0.30 0.02 0.28 55
59 Muhamad 82 M 5 ˇ ˇ × ˇ 25.0 124/74 AW 136 104 45 10 10 0.51 0.03 0.48 55
60 Hajrabeen 68 F 5 × ˇ × × 24.0 110/70 IW 176 124 38 8 8 0.42 0.04 0.38 60
61 Arumugam 72 M 2 ˇ ˇ × × 18.5 120/70 AW 185 137 42 9 9 0.37 0.04 0.33 45
62 Udayakumar 58 M 5 ˇ ˇ × × 25.0 110/70 AW 147 117 45 10 10 0.38 0.08 0.30 55
63 Chitrambalam 45 F 2 × × × × 20.5 120/40 AW 132 106 39 8 12 0.44 0.06 0.38 60
64 Saroja 54 F 1 × × ˇ × 22.0 130/80 IW 176 126 35 12 14 0.40 0.06 0.34 55
65 Chandra 78 F 2 × × × × 19.0 124/74 AW 167 114 42 10 10 0.38 0.04 0.34 48
66 Rajasekar 48 M 5 × × × × 24.0 130/80 AW 197 127 35 9 7 0.42 0.06 0.36 58
67 Ravisankar 54 M 1 × × × × 22.0 120/80 AW 136 98 44 15 17 0.37 0.03 0.34 55
68 Sarangan 63 M 4 × × × × 23.0 110/70 IW 187 122 36 12 12 0.4 0.06 0.34 60
69 Munirathnam 72 M 5 × ˇ ˇ × 21.5 120/70 AW 156 132 42 8 6 0.44 0.04 0.40 58
70 Guruswamy 48 M 4 × ˇ ˇ × 19.5 120/80 AW 134 127 44 10 10 0.34 0.02 0.32 60
71 Meenamma 58 M 2 × × × ˇ 22.1 130/86 AW 157 126 38 9 9 0.36 0.04 0.32 55
72 sindamani 58 F 3 ˇ ˇ × ˇ 20.0 126/76 AW 176 147 34 12 14 0.48 0.06 0.42 60
73 Vetrivel 72 M 4 × ˇ × × 19.5 112/70 IW 165 125 42 8 6 0.42 0.04 0.38 55
74 Andal 52 F 5 ˇ ˇ × × 21.5 120/70 AW 152 107 36 10 10 0.36 0.06 0.30 55
75 Kanagaraj 48 M 2 ˇ ˇ × × 18.5 110/70 AW 136 98 40 6 8 0.40 0.08 0.32 50
76 Kannan 56 M 2 × × × × 20.0 120/80 IW 167 127 48 14 17 0.56 0.10 0.40 60
77 Lakshmi 86 F 4 × × × ˇ 24.0 130/90 AW 159 116 54 20 18 0.64 0.16 0.54 55
78 Kandasamy 64 M 5 × × ˇ × 19.0 130/86 AW 173 129 46 9 8 0.80 0.20 0.60 60
79 Natarajan 52 M 3 × × × × 22.5 120/76 AW 112 86 50 10 10 0.96 0.16 0.80 60
80 Lingusamy 57 M 2 × × × ˇ 24.0 130/80 AW 136 110 54 9 9 0.9 0.10 0.80 58
81 Neelambari 68 F 1 × × × ˇ 19.0 126/76 IW 176 127 48 12 14 0.36 0.06 0.30 55
82 Saroja 48 M 5 ˇ × × × 22.5 128/78 AW 167 111 52 10 10 0.54 0.06 0.48 55
83 Alagesan 59 M 2 ˇ × × × 24.0 130/90 AW 156 142 48 12 10 0.36 0.06 0.30 60
84 Mohan 65 M 5 × × × ˇ 19.0 120/70 AW 165 136 36 10 12 0.42 0.08 0.34 60
85 Babu 57 M 1 × × ˇ × 22.0 110/70 AW 190 112 52 8 9 0.38 0.08 0.50 55
86 Manoharan 65 M 2 × × × × 28.0 130/80 IW 156 102 42 7 8 0.64 0.06 0.58 60
87 Andalammal 70 F 3 × × × ˇ 24.0 120/70 AW 134 100 38 9 10 0.72 0.08 0.64 55
88 Irudayaraj 60 M 5 × × × ˇ 22.2 110/80 AW 176 146 48 12 14 0.38 0.10 0.28 60
89 Ambika 54 F 4 ˇ × × × 25.5 120/86 AW 182 132 54 16 16 0.46 0.06 0.40 55
90 Egambaram 67 M 3 ˇ × × × 19.5 130/70 AW 171 156 42 17 17 0.71 0.11 0.60 50
91 Periyasamy 78 M 2 × × × ˇ 18.0 140/90 IW 146 110 48 9 9 0.34 0.04 0.30 60
92 Nisha 65 F 1 × × ˇ × 22.5 130/70 IW 158 124 52 12 12 0.42 0.10 0.32 55
93 Radhakrishnan 72 M 4 × × × × 24.5 120/80 AW 164 136 42 37 36 0.76 0.16 0.60 60
94 Aravindan 54 M 5 × × × ˇ 28.5 110/70 AW 176 142 36 22 24 0.32 0.06 0.26 55
95 Thiraiseelan 79 M 3 × × × ˇ 30.5 126/90 AW 145 112 34 18 18 0.30 0.06 0.24 45
96 Nandagopal 67 M 2 ˇ × × × 22.0 130/86 AW 180 170 35 12 6 0.38 0.06 0.26 56
97 Kannagi 56 F 1 ˇ × × × 24.5 120/80 AW 154 111 42 8 8 0.46 0.08 0.09 57
98 Periaswamy 76 M 2 ˇ × × × 22.0 112/70 AW 165 125 44 6 12 0.71 0.06 0.45 59
99 Rukumany 69 F 3 ˇ × × × 24.0 120/70 AW 156 138 45 8 14 0.86 0.07 0.67 62
100 kumaraswamy 72 M 4 ˇ × × × 26.0 120/80 AW 165 127 48 6 16 0.88 0.09 0.78 67
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S.NO Name Age Sex DM HT
Family 
History Smoker BMI BP Lipid Profile Liver Enzymes   Serum bilirubin EF
T.Chol LDL HDL AST ALT T D ID
1 Manikandan 56 M 2 Yrs × × × 24.0 120/86 112 152 55 12 11 0.42 0.5 0.3 60
2 Elumalai 66 M × × × ˇ 22.0 126/60 170 136 35 10 8 0.76 0.11 0.40 55
3 Vijaya 55 F × × ˇ × 19.5 130/80 170 112 42 8 8 0.32 0.08 0.32 50
4 Egambaram 67 M × × × × 23.0 110/90 180 85 34 6 10 0.30 0.12 0.4 48
5 Ananavel 56 M × × × ˇ 20.5 120/80 112 75 36 9 13 0.76 0.08 0.28 50
6 Meena 45 F × × × ˇ 18.5 130/80 146 86 58 10 9 0.66 0.11 0.31 60
7 Govindammal 60 F ˇ × × × 22.5 120/80 118 126 48 8 6 0.46 0.06 0.32 55
8 Vijayalakshmi 50 F ˇ × × × 20.5 120/70 136 112 56 12 10 0.98 0.09 0.37 60
9 Ragavan 75 M × × ˇ × 22.5 130/80 146 96 52 10 8 0.96 0.06 0.27 50
10 Muthusamy 67 M × × × × 24.0 120/76 156 117 49 8 12 0.76 0.12 0.56 60
11 Kamala 75 F × × × × 21.0 130/80 112 96 56 7 8 1.00 0.07 0.51 55
12 Unnamalai 55 F × × × × 20.5 120/80 124 120 58 12 6 1.00 0.10 0.50 52
13 Munusamy 47 M × × × × 21.5 130/80 136 107 55 9 10 0.46 0.09 0.40 55
14 Muthusamy 58 M × ˇ ˇ × 19.5 120/70 176 147 36 12 6 1.20 0.06 0.30 54
15 Dhanabagiyam 62 F × ˇ ˇ × 21.5 130/86 110 86 68 10 9 0.56 0.13 0.60 64
16 Vasanthakumari 50 F × × × ˇ 23.4 120/80 196 142 58 8 12 0.90 0.05 0.38 60
17 Anbarasu 47 M ˇ ˇ × ˇ 21.5 120/70 164 98 45 10 10 0.94 0.04 0.35 60
18 Ezhilarasan 55 M × ˇ × × 19.5 120/80 146 86 64 8 13 0.74 0.09 0.43 60
19 Lalitha 62 F ˇ ˇ × × 21.0 110/76 136 118 48 10 10 0.68 0.03 0.28 55
20 Ezhilsundar 38 M ˇ ˇ × × 24.5 130/80 146 126 58 8 10 0.48 0.06 0.43 60
21 Elamaran 72 M × × × × 20.0 116/70 179 132 64 6 10 0.68 0.68 0.30 62
22 Rani 57 F × × × × 24.0 120/74 148 95 58 9 8 0.70 0.06 0.60 45
23 Sachi 67 M × × × × 22.0 120/70 164 102 46 12 6 0.86 0.05 0.37 55
24 Krishnamoothy 58 M × × ˇ × 21.5 136/86 136 84 64 10 9 0.36 0.08 0.48 60
25 Annapoorana 40 F × × × × 21.5 120/76 176 132 32 8 12 0.90 0.02 0.30 45
26 Kuppan 76 M × × × × 19.5 126/70 154 112 45 10 10 0.68 0.05 0.34 56
27 Balakrishnan 48 M × × × × 20.5 136/70 140 119 41 8 8 0.86 0.06 0.41 52
28 Malar 40 F × × × × 21.0 124/74 156 124 54 6 8 0.97 0.08 0.55 60
29 Chinasamy 52 M × ˇ ˇ × 24.0 120/70 136 94 62 12 14 0.76 0.04 0.32 48
30 Dhamasekar 62 M × ˇ ˇ × 21.0 120/80 176 142 38 9 8 0.82 0.04 0.24 45
31 Dhanabakiyam 42 F × × × ˇ 24.5 110/76 156 116 54 14 14 0.90 0.08 0.52 60
32 Chitrambalam 55 M ˇ ˇ × ˇ 23.0 124/74 142 92 58 10 10 0.45 0.06 0.42 55
33 Thulukannama 72 F × ˇ × × 20.0 120/70 136 100 45 11 12 1.00 0.03 0.28 50
34 Dhanajeyan 55 M ˇ ˇ × × 26.5 110/70 148 110 54 8 9 0.7 0.07 0.45 60
35 Mahalakshmi 50 F ˇ ˇ × × 22.5 120/76 148 106 45 10 11 0.64 0.04 0.35 55
36 Dhamotharan 56 M × × × × 28.5 130/70 154 98 48 8 8 0.86 0.04 0.40 60
37 Rooparathi 70 F × × × × 20.0 126/70 174 102 54 10 10 0.96 0.04 0.39 58
38 Marlene Jones 58 F × × ˇ × 26.5 112/08 164 106 48 12 14 0.48 0.03 0.27 52
39 Esakian 62 M × × × × 22.0 130/80 194 124 36 8 8 1.02 0.16 0.60 60
40 Fathimabegam 65 M × × × × 24.5 126/76 164 85 64 12 13 0.68 0.07 0.40 55
41 Gunasekar 40 M × × × × 35.0 130/70 146 76 58 8 10 0.90 0.08 0.60 60
42 Rajamanikam 54 M × × × × 21.0 120/74 156 90 52 12 12 0.86 0.07 0.43 55
43 Harikrishnan 65 M × ˇ ˇ × 24.0 132/72 176 124 48 8 6 1.20 0.05 0.40 60
44 Rangamma 50 F × ˇ ˇ × 24.5 120/74 142 96 58 12 10 0.60 0.06 0.46 55
45 Chinnadurai 72 M × × × ˇ 21.0 110/70 136 72 82 6 8 0.94 0.10 0.80 60
46 Lalli 40 F ˇ ˇ × ˇ 22.0 120/76 148 88 44 7 7 0.88 0.04 0.33 52
47 asantha srinivasa 55 M × ˇ × × 24.0 130/70 164 88 49 12 12 0.76 0.04 0.24 45
48 Meenambigai 62 F ˇ ˇ × × 25.0 120/70 136 72 64 8 8 0.42 0.03 0.38 48
49 Chinnasamy 74 M ˇ ˇ × × 22.5 110/70 170 106 46 7 7 0.46 0.1 0.29 40
50 Alamelu 60 F × × × × 19.0 120/80 156 120 48 12 12 0.56 0.07 0.44 50
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51 Egavalli 40 F × × ˇ × 21.0 130/70 146 86 54 8 8 0.76 0.04 0.28 48
52 Palani 54 M × × × × 21.5 120/80 134 76 86 12 12 0.60 0.03 0.37 50
53 Kandasamy 65 M × × × × 23.5 120/70 176 142 36 20 20 0.78 0.02 0.38 55
54 Indumathi 46 F × × × × 20.0 110/70 165 106 48 9 9 0.42 0.03 0.36 45
55 Bharathy 45 F × × × × 21.0 120/70 132 82 46 8 9 0.86 0.06 0.35 60
56 Sivakami 35 F × ˇ ˇ × 21.5 124/80 184 106 52 10 12 0.94 0.06 0.48 55
57 Kuppan 72 M × ˇ ˇ × 23.5 110/78 164 112 54 14 17 0.62 0.05 0.32 60
58 Subramaniyan 65 M × × × ˇ 20.0 120/76 154 89 64 9 8 0.86 0.02 0.28 55
59 Chellamal 67 F ˇ ˇ × ˇ 21.5 130/70 178 104 52 7 7 0.94 0.03 0.48 55
60 Gandhi 45 M × ˇ × × 22.5 140/90 184 116 46 8 8 0.62 0.04 0.38 60
61 Umarani 50 F ˇ ˇ × × 23.5 120/80 187 142 48 10 10 0.86 0.04 0.33 45
62 Kanniyammal 55 F ˇ ˇ × × 24.0 112/70 134 86 64 12 12 0.96 0.08 0.30 55
63 Muniyan 45 M × × × × 21.0 120/80 146 74 54 10 10 1.08 0.06 0.38 60
64 Sivakumar 54 M × × ˇ × 27.8 130/86 167 142 36 8 8 0.82 0.06 0.34 55
65 Thangavel 75 M × × × × 28.4 128/70 132 82 62 6 6 0.54 0.04 0.34 48
66 Ganesan 35 F × × × × 20.5 124/68 148 86 56 7 8 0.78 0.06 0.36 58
67 Sivagami 65 F × × × × 26.0 124/76 146 80 51 6 8 0.89 0.03 0.34 55
68 Ranganayagi 72 M × × × × 23.0 132/72 176 126 52 10 12 0.68 0.06 0.34 60
69 Neelakandan 58 F × ˇ ˇ × 25.0 126/78 158 112 48 14 14 0.56 0.04 0.40 58
70 Ramani 54 M × ˇ ˇ × 38.5 110/80 148 82 54 20 22 0.48 0.02 0.32 60
71 Balaraman 48 M × × × ˇ 22.5 120/76 134 96 46 20 17 0.36 0.04 0.32 55
72 Ulaganadhan 52 F ˇ ˇ × ˇ 24.0 130/74 142 76 50 18 13 0.98 0.06 0.42 60
73 Veeralakshmi 54 M × ˇ × × 22.0 120/80 124 76 68 16 10 0.90 0.04 0.38 55
74 Ramkumar 48 M ˇ ˇ × × 26.5 140/70 142 102 42 12 12 0.88 0.06 0.30 55
75 Palanisamy 65 F ˇ ˇ × × 27.0 120/70 182 92 36 16 10 0.78 0.08 0.32 50
76 Selvamary 66 M × × × × 20.5 120/80 164 96 52 8 8 0.36 0.10 0.40 60
77 Sundaram 40 F × × × ˇ 23.5 130/76 128 84 46 8 6 0.46 0.16 0.54 55
78 Kanagavalli 82 M × × ˇ × 23.0 120/80 163 118 55 7 7 0.76 0.20 0.60 60
79 Swetha 40 F × × × × 24.5 142/80 121 102 60 6 12 0.92 0.16 0.80 60
80 Manikandan 62 M × × × ˇ 26.7 126/76 163 129 42 10 14 0.88 0.10 0.80 58
81 Devendran 65 M × × × ˇ 19.0 110/70 129 79 59 14 18 0.59 0.06 0.30 55
82 Senthilkumar 60 M ˇ × × × 28.5 120/80 198 149 56 28 22 0.47 0.06 0.48 55
83 Padmavathy 45 F ˇ × × × 29.0 120/70 147 129 52 16 14 0.79 0.06 0.30 60
84 Sridar 72 M × × × ˇ 32.5 120/80 156 92 48 14 14 0.78 0.08 0.34 60
85 Saminathan 68 M × × ˇ × 28.0 132/82 163 101 44 12 12 0.97 0.08 0.50 55
86 Kalairani 40 F × × × × 24.5 130/70 136 96 58 8 10 0.85 0.06 0.58 60
87 Vadivel 65 M × × × ˇ 20.5 120/72 176 92 42 6 8 0.36 0.08 0.64 55
88 anthonyammal 50 F × × × ˇ 21.5 112/70 131 91 63 7 9 0.76 0.10 0.28 60
89 Ramanan 55 M ˇ × × × 22.0 130/80 152 99 55 11 10 0.42 0.06 0.40 55
90 Devan 40 M ˇ × × × 24.0 118/70 142 82 48 12 13 0.72 0.11 0.60 50
91 Chinnathai 43 F × × × ˇ 23.5 130/80 198 149 32 15 17 0.88 0.04 0.30 60
92 Gangadharan 70 M × × ˇ × 22.5 120/76 169 119 39 19 17 0.39 0.10 0.32 55
93 Janaki 50 F × × × × 24.0 128/72 138 72 49 22 17 0.72 0.16 0.60 60
94 Egambaram 65 M × × × ˇ 26.0 110/70 151 107 54 12 14 0.84 0.06 0.26 55
95 Muniyan 45 M × × × ˇ 19.0 120/80 127 72 65 3 16 0.62 0.06 0.24 45
96 Murugammal 46 F ˇ × × × 18.5 140/90 163 163 103 42 20 18 0.06 0.26 56
97 Gowrisankar 48 M ˇ × × × 27.5 120/86 178 142 44 10 12 0.36 0.08 0.09 57
98 Saraswathi 56 F × × × ˇ 26.0 120/70 165 132 46 18 13 0.38 0.07 0.06 58
99 Samundeswari 65 F ˇ × × × 23.5 130/80 178 112 54 12 14 0.78 0.08 0.09 56
100 Jeeva 70 M ˇ × × × 27.5 112/70 163 132 65 18 12 0.46 0.06 0.28 60
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